Generex has been awarded the 2006 North American Frost & Sullivan Award for Technology Innovation for its proprietary oral insulin spray product, Generex Oral-lyn.

Frost & Sullivan's Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry at hand. In this case, Frost & Sullivan is awarding Generex Oral-lyn as a product that is strongly positioned to be the most acceptable form of alternative, needle-free insulin delivery. This award recognizes the quality and depth of Generex's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

The significance of Oral-lyn is growing in importance because of its ability to control blood sugar rises after meals. There is mounting evidence that post meal glucose control is a key factor in reducing cardiovascular risk associated with diabetes. For those who keep asking - the CFO has informed me that they are looking into other options that will get Oral-lyn into the hands (and mouths) of US diabetics by sometime in 2007.